UniProt ID | REL_HUMAN | |
---|---|---|
UniProt AC | Q04864 | |
Protein Name | Proto-oncogene c-Rel | |
Gene Name | REL | |
Organism | Homo sapiens (Human). | |
Sequence Length | 619 | |
Subcellular Localization | Nucleus. | |
Protein Description | Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator.. | |
Protein Sequence | MASGAYNPYIEIIEQPRQRGMRFRYKCEGRSAGSIPGEHSTDNNRTYPSIQIMNYYGKGKVRITLVTKNDPYKPHPHDLVGKDCRDGYYEAEFGQERRPLFFQNLGIRCVKKKEVKEAIITRIKAGINPFNVPEKQLNDIEDCDLNVVRLCFQVFLPDEHGNLTTALPPVVSNPIYDNRAPNTAELRICRVNKNCGSVRGGDEIFLLCDKVQKDDIEVRFVLNDWEAKGIFSQADVHRQVAIVFKTPPYCKAITEPVTVKMQLRRPSDQEVSESMDFRYLPDEKDTYGNKAKKQKTTLLFQKLCQDHVETGFRHVDQDGLELLTSGDPPTLASQSAGITVNFPERPRPGLLGSIGEGRYFKKEPNLFSHDAVVREMPTGVSSQAESYYPSPGPISSGLSHHASMAPLPSSSWSSVAHPTPRSGNTNPLSSFSTRTLPSNSQGIPPFLRIPVGNDLNASNACIYNNADDIVGMEASSMPSADLYGISDPNMLSNCSVNMMTTSSDSMGETDNPRLLSMNLENPSCNSVLDPRDLRQLHQMSSSSMSAGANSNTTVFVSQSDAFEGSDFSCADNSMINESGPSNSTNPNSHGFVQDSQYSGIGSMQNEQLSDSFPYEFFQV | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MASGAYNPY ------CCCCCCCCC | 19.37 | 22814378 | |
3 | Phosphorylation | -----MASGAYNPYI -----CCCCCCCCCE | 23.74 | 23186163 | |
6 | Phosphorylation | --MASGAYNPYIEII --CCCCCCCCCEEEE | 21.86 | 24719451 | |
26 | Sumoylation | RGMRFRYKCEGRSAG CCCCEEEEECCCCCC | 22.89 | - | |
26 | Sumoylation | RGMRFRYKCEGRSAG CCCCEEEEECCCCCC | 22.89 | - | |
31 | Phosphorylation | RYKCEGRSAGSIPGE EEEECCCCCCCCCCC | 48.08 | 20873877 | |
34 | Phosphorylation | CEGRSAGSIPGEHST ECCCCCCCCCCCCCC | 25.90 | 24719451 | |
46 | Phosphorylation | HSTDNNRTYPSIQIM CCCCCCCCCCEEEEE | 41.74 | 29507054 | |
47 | Phosphorylation | STDNNRTYPSIQIMN CCCCCCCCCEEEEEE | 7.55 | 24043423 | |
49 | Phosphorylation | DNNRTYPSIQIMNYY CCCCCCCEEEEEEEE | 19.40 | 24043423 | |
55 | Phosphorylation | PSIQIMNYYGKGKVR CEEEEEEEECCCEEE | 9.01 | 24043423 | |
56 | Phosphorylation | SIQIMNYYGKGKVRI EEEEEEEECCCEEEE | 13.83 | 24043423 | |
68 | Acetylation | VRITLVTKNDPYKPH EEEEEEECCCCCCCC | 52.45 | 25953088 | |
82 | Ubiquitination | HPHDLVGKDCRDGYY CCCCCCCCCCCCCCE | 46.29 | 29967540 | |
88 | Phosphorylation | GKDCRDGYYEAEFGQ CCCCCCCCEECCCCC | 11.47 | 22817900 | |
89 | Phosphorylation | KDCRDGYYEAEFGQE CCCCCCCEECCCCCC | 17.75 | 22817900 | |
176 | Phosphorylation | PVVSNPIYDNRAPNT CCCCCCCCCCCCCCC | 14.39 | 28064214 | |
210 | Ubiquitination | EIFLLCDKVQKDDIE EEEEEECCCCCCCCE | 45.64 | 29967540 | |
210 | Acetylation | EIFLLCDKVQKDDIE EEEEEECCCCCCCCE | 45.64 | 25953088 | |
254 | O-linked_Glycosylation | PPYCKAITEPVTVKM CCCCCCCCCCEEEEE | 38.81 | 27454154 | |
258 | O-linked_Glycosylation | KAITEPVTVKMQLRR CCCCCCEEEEEEECC | 25.73 | 27454154 | |
267 | Phosphorylation | KMQLRRPSDQEVSES EEEECCCCCHHHHHH | 50.55 | 21082442 | |
350 (in isoform 2) | O-linked_Glycosylation | - | 5.62 | 27454154 | |
359 | Phosphorylation | GSIGEGRYFKKEPNL CCCCCCCCCCCCCCC | 30.52 | 22817900 | |
368 | Phosphorylation | KKEPNLFSHDAVVRE CCCCCCCCCCEEEEE | 24.51 | 28555341 | |
378 | O-linked_Glycosylation | AVVREMPTGVSSQAE EEEEECCCCCCCCCH | 49.24 | 27454154 | |
382 | O-linked_Glycosylation | EMPTGVSSQAESYYP ECCCCCCCCCHHCCC | 30.88 | 27454154 | |
386 | Phosphorylation | GVSSQAESYYPSPGP CCCCCCHHCCCCCCC | 32.74 | - | |
387 | Phosphorylation | VSSQAESYYPSPGPI CCCCCHHCCCCCCCC | 15.76 | - | |
409 | O-linked_Glycosylation | ASMAPLPSSSWSSVA CCCCCCCCCCCCCCC | 44.69 | 27454154 | |
421 | Methylation | SVAHPTPRSGNTNPL CCCCCCCCCCCCCCC | 60.72 | 115386197 | |
422 | Phosphorylation | VAHPTPRSGNTNPLS CCCCCCCCCCCCCCC | 37.28 | 28555341 | |
425 | Phosphorylation | PTPRSGNTNPLSSFS CCCCCCCCCCCCCCC | 41.56 | 28555341 | |
425 | O-linked_Glycosylation | PTPRSGNTNPLSSFS CCCCCCCCCCCCCCC | 41.56 | 27454154 | |
429 | Phosphorylation | SGNTNPLSSFSTRTL CCCCCCCCCCCCCCC | 30.51 | 28857561 | |
430 | Phosphorylation | GNTNPLSSFSTRTLP CCCCCCCCCCCCCCC | 30.79 | 28857561 | |
433 | Phosphorylation | NPLSSFSTRTLPSNS CCCCCCCCCCCCCCC | 26.18 | - | |
435 | Phosphorylation | LSSFSTRTLPSNSQG CCCCCCCCCCCCCCC | 43.01 | 28555341 | |
438 | Phosphorylation | FSTRTLPSNSQGIPP CCCCCCCCCCCCCCC | 52.83 | 28555341 | |
492 | Phosphorylation | ISDPNMLSNCSVNMM CCCHHHHCCCEEEEE | 25.64 | 16585559 | |
503 | Phosphorylation | VNMMTTSSDSMGETD EEEEECCCCCCCCCC | 31.45 | 10823840 | |
516 | Phosphorylation | TDNPRLLSMNLENPS CCCCCEEEECCCCCC | 15.37 | 28348404 | |
523 | Phosphorylation | SMNLENPSCNSVLDP EECCCCCCCCCCCCH | 37.20 | 16585559 | |
526 | Phosphorylation | LENPSCNSVLDPRDL CCCCCCCCCCCHHHH | 28.52 | 16585559 | |
557 | Phosphorylation | SNTTVFVSQSDAFEG CCCEEEECCHHHCCC | 16.71 | 22817900 | |
597 | Phosphorylation | GFVQDSQYSGIGSMQ CCCCCCCCCCCCCCC | 16.90 | 22817900 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
267 | S | Phosphorylation | Kinase | PKA | - | Uniprot |
516 | S | Phosphorylation | Kinase | CHUK | O15111 | GPS |
516 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
526 | S | Phosphorylation | Kinase | CHUK | O15111 | GPS |
526 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
557 | S | Phosphorylation | Kinase | CHUK | O15111 | GPS |
557 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of REL_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of REL_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...